SAN FRANCISCO (GenomeWeb) – Researchers are turning to next-generation sequencing to develop better methods for cataloguing mutations that confer tuberculosis drug resistance and, ultimately, to design better diagnostics.

According to the World Health Organization, 80 percent of people infected with multi-drug resistant tuberculosis in 2015 did not receive the appropriate treatment, and only half of those who started treatment were cured. This is compared to a more than 90 percent cure rate for tuberculosis that is not resistant.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.